Objective To explore the clinical efficacy and safety of lurasidone in treating patients with schizophrenia and its influence on cognitive function.
Methods A total of 80 patients with schizophrenia were selected and randomly divided into study group (treated with lurasidone) and control group (treated with quetiapine), with 40 cases in each group. After 12 weeks of treatment, the efficacy of the drugs was evaluated by the Positive and Negative Syndrome Scale (PANSS). The patient's neurocognitive function was evaluated by the Wisconsin Card Sorting Test (WCST) and the Paced Auditory Serial Addition Test (PASAT).
Results After treatment, there was no significant difference in the therapeutic effective rate between the two groups (P>0.05), but there were significant between-group differences in adverse reactions such as excessive sedation, drowsiness, abnormal electrocardiogram, abnormal liver function and weight gain (P < 0.05). The study group showed significant improvements in WCST total scores and perseverative errors before and after treatment, and the improvements in the study group were also significantly better than those in the control group after treatment.
Conclusion Lurasidone and quetiapine have similar clinical efficacy in the treatment of schizophrenia, but lurasidone is able to achieve more significant improvement in cognitive impairments and adverse effects related to schizophrenia.
DownLoad: